When claims are drawn from these sources, they are attributed to "Omzo's published materials" or "per Omzo's Terms." FDA.gov primary sources: The FDA's public page on unapproved GLP-1 drugs, the April 30, 2026 FDA press release on the 503B Bulks List proposal, and the Federal Register notice 91 Fed
Generic versions remain 5 to 7+ years away, but manufacturer competition and government pressure are driving prices lower faster than the patent timeline alone would suggest
Neuroscience (2015) :303:4250
But for the majority of people currently searching this topic cash-pay patients without GLP-1 insurance coverage , new patients who need a prescription quickly, and people who live outside the 20-plus cities where One Medical operates Amazon's program has structural limitations that most coverage of the launch has not addressed clearly
About 15% to 45% of patients will experience these side effects
What Changes Once Retatrutide Is Approved FDA approval would shift retatrutide from investigational to standard prescription